Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

May 23, 2022

Study Completion Date

June 29, 2022

Conditions
Lennox Gastaut Syndrome
Interventions
DRUG

Carisbamate

An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)

Trial Locations (7)

19104

Hospital of the University of Pennsylvania, Philadelphia

21210

Johns Hopkins Hospital, Baltimore

27710

Duke Health, Durham

84113

The University of Utah School of Medicine - Primary Children's Hospital (Primary Children's Medical Center), Salt Lake City

97239

Oregon Health and Science University, Portland

98055

UW Valley Medical Center, Renton

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

SK Life Science, Inc.

INDUSTRY

NCT03731715 - Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome | Biotech Hunter | Biotech Hunter